Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTP-692 MAD study in healthy volunteers
NCT03880253Phase 1Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Apr 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of deutarserine in schizophrenia, sponsored by Concert Pharmaceuticals. Primary endpoints: Number of participants with adverse events and Measurement of CTP-692 exposure in plasma. Started Apr 2019; status: completed.
02
Drugs
deutarserine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03880253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03880253.